

## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/807, 647A
Source: 9/6/2002
Date Processed by STIC: 8/6/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
- 3. Hand Carry directly to:

ì

U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202

U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

## **Raw Sequence Listing Error Summary**

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 9/807,649A
ATTN: NEW RULES CASES:	PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
1Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces,
3Misaligned Amino Numbering	The numbering under each 5 <sup>th</sup> amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
8 V Skipped Sequences (NEW RULES)	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.  Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.  <210> sequence id number  <400> sequence id number  000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing.  Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.  Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.  (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
12PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

AMC/MH - Biotechnology Systems Branch - 08/21/2001



PCT09

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/807,647A

DATE: 08/06/2002
TIME: 16:48:31

Input Set : A:\2560USOPSeq.txt

Output Set: N:\CRF3\08062002\1807647A.raw

Doos No walling

```
Corrected Diskette Needec
      3 <110> APPLICANT: OI, Satoru
              SUZUKI, Nobuhiro
      4
              MATSUMOTO, Takahiro
     7 <120> TITLE OF INVENTION: 1,5-Benzodiazepine Compounds, Their Production and Use
      9 <130> FILE REFERENCE: 2560 USOP
     11 <140> CURRENT APPLICATION NUMBER: 09/807,647A
     12 <141> CURRENT FILING DATE: 2001-06-29
     14 <160> NUMBER OF SEQ ID NOS: 10
                                                                      Does Not Comply
     16 <170> SOFTWARE: PatentIn version 3.0
                                                                 Corrected Diskette Needed
     18 <210> SEQ ID NO: 1
     19 <211> LENGTH: 30
     20 <212> TYPE: DNA
C--> 21 <213> ORGANISM: Artificial
     23 <220> FEATURE:
     24 <223> OTHER INFORMATION: oligomer S1-1 based on human SSTRIC DNA
     '26 <400> SEQUENCE: 1
     27 ggtcgacctc agctaggatg ttccccaatg
                                                                                30
     30 <210> SEQ ID NO: 2
     31 <211> LENGTH: 28
     32 <212> TYPE: DNA
C--> 33 <213> ORGANISM: Artificial
     35 <220> FEATURE:
     36 <223> OTHER INFORMATION: oligomer S1-2 based on human SSTRIC DNA
     38 <400> SEQUENCE: 2
     39 ggtcgacccg ggctcagagc gtcgtgat
                                                                                28
     42 <210> SEQ ID NO: 3
     43 <211> LENGTH: 28
     44 <212> TYPE: DNA
C--> 45 <213> ORGANISM: Artificial
     47 <220> FEATURE:
     48 <223> OTHER INFORMATION: oligomer PT-1 based on human SSTR2 DNA
     50 <400> SEQUENCE: 3
     51 ggtcgacacc atggacatgg cggatgag
                                                                                28
     54 <210> SEQ ID NO: 4
     55 <211> LENGTH: 26
     56 <212> TYPE: DNA
C--> 57 <213> ORGANISM: Artificial
     59 <220> FEATURE:
     60 <223> OTHER INFORMATION: Primer sequence
     62 <400> SEQUENCE: 4
     63 ggtcgacagt tcagatactg gtttgg
                                                                                26
     66 <210> SEQ ID NO: 5
```

67 <211> LENGTH: 30

RAW SEQUENCE LISTING

DATE: 08/06/2002

PATENT APPLICATION: US/09/807,647A

TIME: 16:48:31

Input Set : A:\2560US0PSeq.txt

Output Set: N:\CRF3\08062002\1807647A.raw

68 <212> TYPE: DNA

C--> 69 <213> ORGANISM: Artificial

71 <220> FEATURE:

72 <223> OTHER INFORMATION: oligomer S3-1 based on human SSTR3 DNA

74 <400> SEQUENCE: 5

75 ggtcgacctc aaccatggac atgcttcatc 30

78 <210> SEQ ID NO: 6

79 <211> LENGTH: 29

80 <212> TYPE: DNA

C--> 81 <213> ORGANISM: Artificial

83 <220> FEATURE:

84 <223> OTHER INFORMATION: oligomer S3-2 based on human SSTR3 DNA

. 86 <400> SEQUENCE: 6

87 ggtcgacttt ccccaggccc ctacaggta 29

90 <210> SEQ ID NO: 7

91 <211> LENGTH: 28

92 <212> TYPE: DNA

C--> 93 <213> ORGANISM: Artificial

95 <220> FEATURE:

96 <223> OTHER INFORMATION: oligomer S4-1 based on human SSTR4 DNA

98 <400> SEQUENCE: 7

99 ggctcgagtc accatgagcg ccccctcg 28

102 <210> SEQ ID NO: 8

103 <211> LENGTH: 0

'104' <212> TYPE: DNA C--> 105 <213> ORGANISM: artificial

107 <220> FEATURE:

108 <223> OTHER INFORMATION: oligomer S4-2 based on human SSTR4 DNA

110 <400> SEQUENCE: 8

W--> 111 000

113 <210> SEQ ID NO: 9

114 <211> LENGTH: 28

115 <212> TYPE: DNA

C--> 116 <213> ORGANISM: Artificial

118 <220> FEATURE:

119 <223> OTHER INFORMATION: oligomer S5-1 based on human SSTR5 cDNA

121 <400> SEQUENCE: 9

122 ggtcgaccac catggagccc ctgttccc

125 <210> SEQ ID NO: 10

126 <211> LENGTH: 26

127 <212> TYPE: DNA

C--> 128 <213> ORGANISM: Artificial

130 <220> FEATURE:

131 <223> OTHER INFORMATION: oligomer S5-2 based on human SSTR5 cDNA

133 <400> SEQUENCE: 10

134 ccgtcgacac tctcacagct tgctgg

is intentional

ten 8

on Enn Junnary

Summary 1

26